Post-authorisation Safety Study (PASS): Retrospective Medical Chart Review of Patients with PAH Newly Treated With Either Uptravi® (selexipag) or any Other PAH-specific Therapy (EXTRACT)

06/10/2022
15/08/2024
EU PAS number:
EUPAS49227
Study
Finalised
Subscribe
Download as PDF
Documents
Study protocol
Initial protocol

15Aug2024-REDACTED_Protocol-FD-67896049PAH0002-588005_1363699.pdf

English (1009.78 KB - PDF) View document
Study results
Study results

15Aug2024-REDACTED_Interim CSR #7-Body-67896049PAH0002_AC-065A401-1119952_1363698.pdf

English (2.52 MB - PDF) View document
Study report
Other information